Report Viewer

NINDS CDE Notice of Copyright
Parkinson's Disease Quality of Life Scale (PDQUALIF)
Please visit this website for more information about the instrument: Parkinson's Disease Quality of Life Scale
NeuroRehab Supplemental - Highly Recommended
Recommendations for use: Indicated for studies requiring a Parkinson's Disease-Specific Health-Related Quality of Life measure.
Supplemental: Parkinson's Disease (PD)
Short Description of Instrument
The Parkinson's Disease Quality of Life Scale (PDQUALIF) is a (Parkinson's) disease-specific health related quality of life questionnaire.
Comments/Special Instructions
The 33-item patient self-report instrument has 32 domain specific items and 1 global item. The 7 subscales measure social/role function (9) self-image/sexuality (7), sleep (3), outlook (4), physical function (5), Independence (2) and urinary function (2).
Scoring and Psychometric Properties
Scoring: Subscale scores are created by transforming raw scores to a 0 to 100 measurement scale by summing the items within a subscale, dividing by the maximum possible total score for that subscale, and multiplying by 100, with lower scores indicating a better quality of life. A total score for the scale was computed by taking an un-weighted average of the individual subscale scores.
Psychometric properties: Psychometric properties are acceptable but have only been assessed by the developing group.
Strengths: The PDQUALIF includes many non-motor items of PD including fatigue, sleep, autonomic dysfunction, and sexual function. Sensitivity to change demonstrated in clinical trials.
Weaknesses: Rarely used.
Key Reference:
Welsh M, McDermott MP, Holloway RG, Plumb S, Pfeiffer R, Hubble J; Parkinson Study Group. Development and testing of the Parkinson's disease quality of life scale. Mov Disord. 2003 Jun;18(6):637-45.
Additional References:
Brown CA, Cheng EM, Hays RD, Vassar SD, Vickrey BG. SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res. 2009 Nov;18(9):1219-37.
Fahn S; Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42.
Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A; Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004 Jul;61(7):1044-53.
Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002 Dec;59(12):1937-43.
Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005 Feb;62(2):241-8.
Schneider RB, Lu X, Biglan K, McDermott MP. Earlier Dopaminergic Treatment in Parkinson's Disease Is Not Associated With Improved Outcomes. Mov Disord Clin Pract. 2019 Jan 28;6(3):222-226.
Document last updated August 2022